ViiV Healthcare’s HIV-1 drug fostemsavir succeeds in phase 3 trial

ViiV Healthcare has reported positive results for its phase 3 BRIGHTE study of investigational fostemsavir at 48 weeks in heavily treatment-experienced (HTE) patients with HIV-1 infection.